Search results
Showing 1606 to 1620 of 8904 results
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
NICE is unable to recommend the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission.
Show all sections
Sections for TA351
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.
View recommendations for TA304Show all sections